Details of the SBP | SYNBIP

General Information of Synthetic Binding Protein (SBP) (ID: SBP002011)
SBP Name	Nanobody M6495
Synonyms	ALX 1141
Molecular Weight	28.1 kDa
Design Method	Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status	Phase I

Protein Scaffold Information of This SBP
Scaffold ID	PS048 Scaffold Info					[1]
Scaffold Name	Nanobody
Scaffold Class	Antibody fragment
Fold Type	Beta-Sheets + Loops

Binding Target(s) of This SBP (BTS)

BTS Name	Details	Mechanism	Application	Affinity	Research Organization	Ref
A disintegrin and metalloproteinase with thrombospondin motifs 5	BTS Info	Inhibitor	Osteoarthritis [ICD-11: FA0Z]	Kd: 0.00365 nM	Ablynx; Merck KGaA; University of Copenhagen	[1]

Clinical Trial Information of This SBP
NCT03224702	Click to show the Detail
Indication	Healthy
Phase	Phase I
Title	A Single-Center, Phase I, Randomized, Double Blind, Placebo-Controlled, First-In-Human Trial to Assess the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Subcutaneous Injected M6495 (Anti-ADAMTS-5 Nanobody) in Healthy Male Subjects
Status	Completed
Sponsor	Merck KGaA, Darmstadt, Germany
NCT03583346	Click to show the Detail
Indication	Symptomatic Knee Osteoarthritis
Phase	Phase I
Title	A Phase Ib, Single-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Injections of M6495 (Anti-ADAMTS-5 Nanobody) in Participants With Symptomatic Knee Osteoarthritis
Status	Completed
Sponsor	Merck KGaA, Darmstadt, Germany

References

1

Inflammation and joint destruction may be linked to the generation of cartilage metabolites of ADAMTS-5 through activation of toll-like receptors. Osteoarthritis Cartilage. 2020 May;28(5):658-668.